VEGF Trap for the treatment of malignant ascites

摘要

in The Lancet Oncology, Michael Untch and colleagues report the first efficacy results from the GeparQuinto (GBG 44) study,1 a randomised phase 3 trial of lapatinib versus trastuzumab in combination with neoadjuvant anthracydine-based and taxane-based chemotherapy.1 620 women with HER2-positive operable or locally advanced breast cancer were randomly assigned to receive lapatinib (a tyrosine-kinase inhibitor of HER1 and HER2) or trastuzumab (a monoclonal antibody to the HER2 receptor), concurrent with a planned regimen of four cycles of an anthracycline (epirubicin 90 mg/m2 plus cydophosphamide 600 mg/m~2) followed by four cycles of a taxane (docetaxel 100 mg/m~2).